Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | AR | P10275 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | PANK3 | Q9H999 | 7/20 | 0.49 |
| ▸ | SMO | Q99835 | 3/20 | 0.48 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | JAK1 | P23458 | 1/20 | 0.47 |
| ▸ | TYK2 | P29597 | 1/20 | 0.47 |
| ▸ | JAK3 | P52333 | 1/20 | 0.47 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12099334 | 0.84 | GPR119 (0.55) | GPR119KDM4EALDH1A1L3MBTL1PANK3 | |
| SCHEMBL12327619 | 0.84 | GPR119 (0.55) | GPR119KDM4EALDH1A1L3MBTL1PANK3 | |
| SCHEMBL1347347 | 0.84 | GPR119 (0.55) | GPR119KDM4EALDH1A1L3MBTL1PANK3 | |
| SCHEMBL12384454 | 0.84 | GPR119 (0.55) | GPR119KDM4EALDH1A1L3MBTL1PANK3 | |
| SCHEMBL20985879 | 0.84 | GPR119 (0.55) | GPR119KDM4EALDH1A1L3MBTL1PANK3 | |
| SCHEMBL9920475 | 0.84 | GPR119 (0.55) | GPR119KDM4EALDH1A1L3MBTL1PANK3 | |
| SCHEMBL16627289 | 0.84 | GPR119 (0.55) | GPR119KDM4EALDH1A1L3MBTL1PANK3 | |
| SCHEMBL12424419 | 0.84 | GPR119 (0.55) | GPR119KDM4EALDH1A1L3MBTL1PANK3 | |
| Hydrochloric Acid SCHEMBL17687617 | 0.83 | GPR119 (0.54) | GPR119KDM4EALDH1A1L3MBTL1PANK3 | |
| Hydrochloric Acid SCHEMBL23297158 | 0.82 | GPR119 (0.54) | GPR119KDM4EALDH1A1L3MBTL1PANK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4400172-A2 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | Incyte Holdings Corporation (US) | 2024-07-17 | — | — | EP | disclosed |
| EP-3715347-B1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | INCYTE HOLDINGS CORP (US) | 2021-12-22 | — | — | EP | disclosed |
| EP-3715347-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | Incyte Holdings Corporation (US) | 2020-09-30 | — | — | EP | disclosed |
| US-10695337-B2 | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2020-06-30 | — | — | US | disclosed |
| EP-3354652-B1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | INCYTE HOLDINGS CORP (US) | 2020-05-06 | — | — | EP | disclosed |
| EP-3354652-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | Incyte Holdings Corporation (US) | 2018-08-01 | — | — | EP | disclosed |
| US-9999619-B2 | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2018-06-19 | — | — | US | disclosed |
| EP-3050882-B1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | INCYTE HOLDINGS CORP (US) | 2018-01-31 | — | — | EP | disclosed |
| US-20170246157-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | INCYTE CORPORATION | 2017-08-31 | — | — | US | disclosed |
| EP-3002283-B1 | THIAZOLE DERIVATIVES | KYOWA HAKKO KIRIN CO LTD (JP) | 2017-06-14 | — | — | EP | disclosed |
| US-9464088-B2 | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2016-10-11 | — | — | US | disclosed |
| US-20140275031-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | INCYTE CORPORATION (US) | 2014-09-18 | — | — | US | disclosed |
| US-8765734-B2 | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors | INCYTE CORPORATION (US) | 2014-07-01 | — | — | US | disclosed |
| US-8461328-B2 | Tricyclic heterocyclic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20120149691-A1 | Pyrrolo [1,2-b] Pyridazine Derivatives as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| WO-2011150356-A1 | HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-12-01 | — | — | WO | disclosed |
| EP-2325175-A1 | 2,4-DIAMINOPYRIMIDINE COMPOUND | Astellas Pharma Inc. (JP) | 2011-05-25 | — | — | EP | disclosed |
| US-7268150-B2 | 2-cyano-4-fluoropyrrolidine derivative or its salt | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2007-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149691-A1 | Pyrrolo [1,2-b] Pyridazine Derivatives as Janus Kinase Inhibitors | JAK1, JAK2, JAK3 | GPR119 4381/4885MAPT 4022/4885AR 4571/4885 |
| US-20140275031-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | JAK1, JAK2, JAK3 | GPR119 1656/4885MAPT 4397/4885AR 2490/4885 |
| US-20170246157-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | JAK1, JAK2, JAK3 | GPR119 1656/4885MAPT 4397/4885AR 2490/4885 |
| US-10695337-B2 | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors | JAK1, JAK2, JAK3 | GPR119 1656/4885MAPT 4397/4885AR 2490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.